17 Jan 2025 BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation Lyon, France & Bangkok, Thailand – January 17, 2025 – BioNet, a global leader in vaccine innovation, proudly announces its…
13 Jan 2025 LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today…
31 Jul 2024 BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) "Monovalent recombinant acellular pertussis vaccine proven to significantly boost immunity…
20 Jul 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing…
11 Jul 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women…
20 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen…
